Evidence map›Paper›PMID 39502338›Full record

ReviewInternational journal of cardiology. Heart & vasculature2024

Breaking boundaries: Ticagrelor monotherapy in high-risk patients.

Balbir Singh, D Prabhakar, Jay Shah, Keshava R, Nakul Sinha, Prafulla Kerkar, Prasant Kumar Sahoo, Rajendra Kumar Premchand Jain, Subhash Chandra, Shuvanan Ray and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of cardiology. Heart & vasculature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Balbir SinghMax Healthcare, 1, 2, Press Enclave Marg, Saket Institutional Area, Hauz Rani, Saket, New Delhi, Delhi 110017, India.
D PrabhakarAshwin Clinic, A G Block Old No 25 New 53, Shanthi Main Road, Anna Nagar, Chennai, Tamil Nadu 600040, India.
Jay ShahHCG Hospital, Mithakhali Cross Roads, Mithakhali, Ahmedabad, Gujarat 380006, India.
Keshava RFortis Hospital, 14, Cunningham Rd, Vasanth Nagar, Bengaluru, Karnataka 560052, India.
Nakul SinhaMedanta Hospital, Sector - A, Pocket - 1, Amar Shaheed Path, Lucknow, Uttar Pradesh 226030, India.
Prafulla KerkarAsian Heart Institute, Bandra E, Mumbai, Maharashtra 400051, India.
Prasant Kumar SahooApollo Hospitals, Sainik School Rd, Unit 15, Gajapati Nagar, Bhubaneswar, Odisha 751005, India.
Rajendra Kumar Premchand JainKrishna Institute of Medical Sciences, 1-8-31/1, Minister Road, Secunderabad, Telangana 500003, India.
Subhash ChandraBLK Max Super Speciality Hospital, Pusa Rd, Radha Soami Satsang, Rajendra Place, New Delhi, 110005, India.
Shuvanan RayFortis Healthcare, Kolkata, West Bengal 700039, India.
Shital SardaMedical Affairs, AstraZeneca Pharma India Ltd, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerotic plaque formation is a leading cause of arterial thrombosis that significantly impacts global health by instigating major adverse cardiovascular events (MACE) like myocardial infarction (MI) and stroke. Platelets are central to this process, leading to the development of antiplatelet therapies, to mitigate MACE risks. The combination of aspirin with a potent P2Y

Indexed as

Antiplatelet therapyBleeding riskDual antiplatelet therapyIschemic riskMonotherapyPercutaneous coronary interventionTicagrelor

Identifiers

PMID39502338
PMCPMC11535354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.